Skip to main content

Table 1 Basic patient characteristics and blood stream infections (BSI).

From: Taurolidine-citrate lock solution (TauroLock) significantly reduces CVAD-associated grampositive infections in pediatric cancer patients

Item

Group 1

(heparin)

Group 2

(TauroLockā„¢)

P value

No. of patients

90

89

-

Male (proportion in %)

51 (57)

60 (67)

0.16

Female (proportion in %)

39 (43)

29 (33)

Ā 

Age (years): median

10.4

7.2

0.52

ā€ƒā€ƒā€ƒIQRĪ”

5.2 to 14.7

3.7 to 16.1

Ā 

ā€ƒā€ƒā€ƒRange

0.2 to 35.2

0.0 to 35.4

Ā 

CVAD utilization days

Ā Ā Ā 

ā€ƒā€ƒā€ƒCumulative No.

6,086

6,705

#

ā€ƒā€ƒā€ƒPort

3,672

3,989

Ā 

ā€ƒā€ƒā€ƒBroviac

2,414

2,716

Ā 

Malignancy No. (%)

Ā Ā 

0.09

ā€ƒā€ƒā€ƒALL

21 (23)

26 (29)

Ā 

ā€ƒā€ƒā€ƒAML

3 (3)

6 (7)

Ā 

ā€ƒā€ƒā€ƒNHL and HD

15 (17)

7 (8)

Ā 

ā€ƒā€ƒā€ƒSolid tumor

30 (33)

22 (25)

Ā 

ā€ƒā€ƒā€ƒZNS

18 (20)

27 (30)

Ā 

ā€ƒā€ƒā€ƒMAS

2 (2)

0 (0)

Ā 

ā€ƒā€ƒā€ƒMDS

0 (0)

1 (1)

Ā 

ā€ƒā€ƒā€ƒLCH

1 (1)

0 (0)

Ā 

Malignancy in relapse No. (%)

16 (18)

13 (15)

0.69

No of patients with

Ā Ā 

0.41

Port (proportion in %)

68 (76)

62 (70)

Ā 

Broviac (proportion in %)

22 (24)

27 (30)

Ā 

CVAD removal due to infection: No. (%)

4 (4.4)

3 (3.4)Ī©

1.00

  1. Group 1 = heparin (2003ā€“2005) vs. group 2 = TauroLockā„¢ (2005ā€“2007)
  2. MAS Hemophagocytic lymphohistiocytosis, MDS myelodysplastic syndrome,
  3. LCH Langerhans Cell Histiocytosis.
  4. * CoNS = Coagulase-negative staphylococci.
  5. Ī” IQR = Interquartile range, 25ā€“75. Percentile
  6. # Utilization days per individual patient were not available; thus, P-values could not be calculated.
  7. Ī© None of these due to Gram positive infections caused by CoNS or MRSE